Adjuvant interferon treatment for melanoma

被引：25

作者：

Agarwala, SS ^{[1
]}

Kirkwood, JM ^{[1
]}

机构：

[1] Univ Pittsburgh, Ctr Hlth, Pittsburgh, PA USA

来源：

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA | 1998年 / 12卷 / 04期

关键词：

D O I：

10.1016/S0889-8588(05)70025-3

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

This article summarizes recent and ongoing efforts in the area of adjuvant interferon treatment for cutaneous melanoma. Interferon therapy targets the immune system in an attempt to cure high-risk melanoma. More than a decade of interferon research has culminated in the successful application of interferon-alpha-2b in melanoma, with significantly prolonged survival in patients at high risk for recurrence after surgical resection.

引用

收藏

页码：823 / +

页数：12

相关论文

共 24 条

[1] PROGNOSIS IN SMALL CELL-CARCINOMA OF THE LUNG - RELATIONSHIP TO HUMAN-MILK FAT GLOBULE-2 (HMFG2) ANTIGEN AND OTHER SMALL-CELL ASSOCIATED ANTIGENS [J].

ALLAN, SG ;

HAY, FG ;

MCINTYRE, MA ;

LEONARD, RCF .

BRITISH JOURNAL OF CANCER, 1987, 56 (04) :485-488

[2]

BOON T, 1992, CANCER SURV, V13, P23

[3] Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging system [J].

Buzaid, AC ;

Ross, MI ;

Balch, CM ;

Soong, SJ ;

McCarthy, WH ;

Tinoco, L ;

Mansfield, P ;

Lee, JE ;

Bedikian, A ;

Eton, O ;

Plager, C ;

Papadopoulos, N ;

Legha, SS ;

Benjamin, RS .

JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (03) :1039-1051

[4] RESULTS OF ADJUVANT INTERFERON STUDY IN WHO MELANOMA PROGRAM [J].

CASCINELLI, N ;

BUFALINO, R ;

MORABITO, A ;

MACKIE, R .

LANCET, 1994, 343 (8902) :913-914

[5]

CASCINELLI N, 1995, P AM ASS CLIN ONCOL, V14, P1296

[6] Quality-of-life - adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: An Eastern Cooperative Oncology Group Study [J].

Cole, BF ;

Gelber, RD ;

Kirkwood, JM ;

Goldhirsch, A ;

Barylak, E ;

Borden, E .

JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (10) :2666-2673

[7]

Coulie Pierre G., 1993, Current Opinion in Oncology, V5, P1043, DOI 10.1097/00001622-199311000-00016

[8] RANDOMIZED, SURGICAL ADJUVANT CLINICAL-TRIAL OF RECOMBINANT INTERFERON ALFA-2A IN SELECTED PATIENTS WITH MALIGNANT-MELANOMA [J].

CREAGAN, ET ;

DALTON, RJ ;

AHMANN, DL ;

JUNG, SH ;

MORTON, RF ;

LANGDON, RM ;

KUGLER, J ;

RODRIGUE, LJ .

JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (11) :2776-2783

[9] COSTS AND BENEFITS OF ADJUVANT THERAPY IN BREAST-CANCER - A QUALITY-ADJUSTED SURVIVAL ANALYSIS [J].

GOLDHIRSCH, A ;

GELBER, RD ;

SIMES, RJ ;

GLASZIOU, P ;

COATES, AS .

JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (01) :36-44

[10]

Grob J. J., 1997, Melanoma Research, V7, pS33